MEDIA AVAILABILITY: CN Police officers available for media interviews during Rail Safety Week
HOMEWOOD, Ill., Sept. 19, 2020 (GLOBE NEWSWIRE) — CN (TSX: CNR) (NYSE: CNI) is offering members of the media the […]
Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer
Trodelvy achieves a 27 percent overall response rate and a 5.9-month median duration of response in heavily-pretreated patients with metastatic […]
Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer
Trodelvy significantly reduced the risk of death by 52 percent, with a median overall survival (OS) of 12.1 months compared […]
Phase 3 NORA data of ZEJULA® (niraparib) demonstrate significant PFS benefit, regardless of biomarker status, with an improved safety profile when given with individualized starting dose regimen in Chinese women with platinum-sensitive recurrent ovarian cancer
The NORA study, presented as a late-breaker oral presentation at the European Society for Medical Oncology (ESMO) 2020 Virtual Congress, […]
